Concord Biotech Ltd

Usha Martin Ltd, Schaeffler India Ltd, Waaree Energies Ltd, Star Health & Allied Insurance Company Ltd are among the other stocks to see a surge in volumes on NSE today, 25 February 2026.Concord Biotech Ltd notched up volume of 70.02 lakh shares by 14:14 IST on NSE, a 70.24 fold spurt over two-week average daily volume of 99683 shares. The stock rose 14.00% to Rs.1,226.80. Volumes stood at 56100 shares in the last session.Usha Martin Ltd recorded volume of 82.46 lakh shares by 14:14 IST on NSE, a 21.22 times surge over two-week average daily volume of 3.89 lakh shares. The stock gained 4.73% to Rs.425.25. Volumes stood at 2.96 lakh shares in the last session.Schaeffler India Ltd recorded volume of 10.37 lakh shares by 14:14 IST on NSE, a 14.32 times surge over two-week average daily volume of 72399 shares. The stock gained 3.94% to Rs.4,245.90. Volumes stood at 2.77 lakh shares in the last session.Waaree Energies Ltd recorded volume of 130.42 lakh shares by 14:14 IST on NSE, a 12.41 times surge over two-week average daily volume of 10.51 lakh shares. The stock lost 9.59% to Rs.2,733.40. Volumes stood at 22.95 lakh shares in the last session.Star Health & Allied Insurance Company Ltd witnessed volume of 24.84 lakh shares by 14:14 IST on NSE, a 11.96 times surge over two-week average daily volume of 2.08 lakh shares. The stock increased 3.11% to Rs.469.80. Volumes stood at 2 lakh shares in the last session.Powered by Capital Market - Live

Jai Balaji Industries Ltd, TVS Holdings Ltd, Usha Martin Ltd and Hero MotoCorp Ltd are among the other gainers in the BSE's 'A' group today, 25 February 2026.Concord Biotech Ltd spiked 11.18% to Rs 1198.6 at 11:45 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 30016 shares were traded on the counter so far as against the average daily volumes of 18992 shares in the past one month. Jai Balaji Industries Ltd soared 10.48% to Rs 67.17. The stock was the second biggest gainer in 'A' group. On the BSE, 10.05 lakh shares were traded on the counter so far as against the average daily volumes of 57591 shares in the past one month. TVS Holdings Ltd surged 6.45% to Rs 15234.15. The stock was the third biggest gainer in 'A' group. On the BSE, 941 shares were traded on the counter so far as against the average daily volumes of 400 shares in the past one month. Usha Martin Ltd advanced 6.00% to Rs 430.85. The stock was the fourth biggest gainer in 'A' group. On the BSE, 2.97 lakh shares were traded on the counter so far as against the average daily volumes of 18724 shares in the past one month. Hero MotoCorp Ltd gained 5.68% to Rs 5822.8. The stock was the fifth biggest gainer in 'A' group. On the BSE, 19750 shares were traded on the counter so far as against the average daily volumes of 16758 shares in the past one month. Powered by Capital Market - Live

Net profit of Concord Biotech declined 15.07% to Rs 64.48 crore in the quarter ended December 2025 as against Rs 75.92 crore during the previous quarter ended December 2024. Sales rose 13.74% to Rs 277.77 crore in the quarter ended December 2025 as against Rs 244.22 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales277.77244.22 14 OPM %35.3840.11 - PBDT108.18114.42 -5 PBT89.44101.15 -12 NP64.4875.92 -15 Powered by Capital Market - Live

Concord Biotech will hold a meeting of the Board of Directors of the Company on 11 February 2026.Powered by Capital Market - Live

Raviraj Karia is a chartered accountant and senior finance leader with more than 23 years of experience across pharmaceuticals, healthcare, clinical research, logistics, and private equity. His career reflects deep expertise in corporate governance, strategic finance, and business partnering, having worked closely with Boards, Promoters, CEOs, and global leadership teams. Across leadership roles at Intas Pharmaceuticals, Sakar Healthcare, Lambda Therapeutics, Shalby Hospitals, Gati, GVFL, and Claris Lifesciences, he has delivered significant impact'managing multi billion dollar financing programs, leading India's largest outbound pharma acquisition, facilitating marquee private equity investments, and executing global audits across Europe, the US, Latin America, and emerging markets. Concord Biotech is a R&D driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It has a presence in more than 70 countries worldwide. The company's consolidated net profit declined 33.6% to Rs 63.58 crore on 20.3% increase in net sales to Rs 247.06 crore in Q2 FY26 over Q2 FY25. The scrip rose 0.20% to Rs 1335 on the BSE.Powered by Capital Market - Live

Net profit of Concord Biotech declined 33.59% to Rs 63.58 crore in the quarter ended September 2025 as against Rs 95.74 crore during the previous quarter ended September 2024. Sales declined 20.35% to Rs 247.06 crore in the quarter ended September 2025 as against Rs 310.18 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales247.06310.18 -20 OPM %35.8243.11 - PBDT104.08143.65 -28 PBT85.68130.34 -34 NP63.5895.74 -34 Powered by Capital Market - Live

Net profit of Concord Biotech declined 36.27% to Rs 62.90 crore in the quarter ended September 2025 as against Rs 98.70 crore during the previous quarter ended September 2024. Sales declined 20.35% to Rs 247.06 crore in the quarter ended September 2025 as against Rs 310.18 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales247.06310.18 -20 OPM %36.6544.06 - PBDT103.92146.60 -29 PBT85.53133.29 -36 NP62.9098.70 -36 Powered by Capital Market - Live

Concord Biotech will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live

The inspection was conducted by EU-GMP authorities from 18 August to 21 August 2025. The company stated that this milestone marks a significant achievement, as the successful outcome not only validates its commitment to global quality standards but also opens avenues to expand its presence in international markets. The EU-GMP approval will allow Concord to explore commercial opportunities across multiple EU territories and other regulated geographies, strengthening its global footprint and supporting its growth strategy. Concord added that the inspection outcome reaffirms its commitment to the highest standards of quality, safety, and regulatory compliance, highlighting its focus on operational excellence and alignment with international regulatory expectations. Concord Biotech is involved in manufacturing fermentation and semi-synthetic biopharmaceutical APIs with immunosuppressants as its key therapeutic segment. The company's consolidated net profit fell 26.1% to Rs 44.06 crore on a 5.5% decline in revenue from operations to Rs 203.99 crore in Q1 FY26 over Q1 FY25. Powered by Capital Market - Live

Concord Biotech announced that the European Union Good Manufacturing Practice (EU-GMP) authorities have conducted their first inspection of its Active Pharmaceutical Ingredients (API) manufacturing facility located at Limbassi. The inspection was carried out from 18 August 2025 to 21 August 2025. This milestone marks a significant achievement for Concord, as a successful EU-GMP inspection not only validates our commitment to global quality standards but also paves the way for expanding our footprint into new international markets. The approval will enable Concord to explore commercial opportunities across various EU territories and other regulated geographies, strengthening our global presence and growth trajectory, said the company. Powered by Capital Market - Live